Lv61
2720 积分 2023-05-29 加入
Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
30天前
已完结
Emerging drugs for the treatment of diabetic nephropathy
2个月前
已完结
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
3个月前
已完结
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
7个月前
已完结
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
7个月前
已完结
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
7个月前
已完结
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
7个月前
已完结
Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease
8个月前
已完结
Tirzepatide for Weight Reduction in Chinese Adults With Obesity
9个月前
已完结
Tirzepatide for Weight Reduction in Chinese Adults With Obesity
9个月前
已完结
皖公网安备34019202002308
